Newsmaker: Constellation Pharmaceuticals

Replete with investor funds, the Cambridge, Massachusetts–based epigenetics firm is taking aim at methylases and demethylases linked to disease.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2010-10, Vol.28 (10), p.997-997, Article 997
1. Verfasser:	Osborne, Randy
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/176 706/648 Agriculture Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Biotechnology industry Chromatin Assembly and Disassembly - drug effects Chromatin Assembly and Disassembly - genetics Corporate profiles DNA Methylation - drug effects Drug Approval Drug Industry - economics Drug Industry - legislation & jurisprudence Enzyme Inhibitors - pharmacology Epigenesis, Genetic - drug effects Funding Genetics Humans Investors Life Sciences news Research Support as Topic - economics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Replete with investor funds, the Cambridge, Massachusetts–based epigenetics firm is taking aim at methylases and demethylases linked to disease.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt1010-997